No major significance, but illustrates that various folks are experimenting with early use for SIRT. However with the medium OS of about 9 months for metastatic pancreatic cancer, the 4 month delay, post 1st chemo, could be considered a tad too late!
Metastatic pancreatic cancer is a very aggressive one to treat, so good to see some research here.
http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e15745
Results: Data from the first 24 patients (79% male, mean age 63 y [range 51-77 y]) were analyzed. ECOG status was 0 (n = 10), 1 (n = 13), and 2 (n = 1). Median (IQR) time from diagnosis to Y-90 resin was 10.2 (6.1) mo. Nine patients had extrahepatic disease. Median (IQR) dose delivered to the right (n = 14), left (n = 2), or whole (n = 8) liver was 1.36 (0.42) GBq. Y-90 resin was given concurrently with first-line chemotherapy in 12/21 patients (57%), with a minimum of 4 mo between the onset of chemotherapy and Y-90 resin treatment. Median OS was 6.0 mo (95% CI: 3.9, 12.5) from Y-90 resin and 16.7 mo (95% CI: 13.3, 26.1) from diagnosis. Five patients experienced a partial response. Most AEs were grade 1 or 2. Three patients had grade 3 AEs (abdominal distension or pain, fatigue, ascites, odynophagia, oral sores, biliary duct dilation), and 4 had grade 3 laboratory values (white blood cells, bilirubin, alkaline phosphatase, albumin). Two patients experienced grade 4 AEs, 1 with peripheral neuropathy and 1 with elevated ALT & AST suggesting post-radioembolization hepatitis. Conclusions: Overall, Y-90 resin was safe, with few serious AEs. Survival in this retrospective study was promising, given the generally poor prognosis for pancreatic adenocarcinoma; however, further investigation is needed.
Add to My Watchlist
What is My Watchlist?